Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zilovertamab - Oncternal Therapeutics

Next Previous
Drug Profile

Zilovertamab - Oncternal Therapeutics

Alternative Names: Cirmtuzumab - Oncternal Therapeutics; UC-961

Latest Information Update: 28 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer California Institute for Regenerative Medicine; Oncternal Therapeutics, Inc.; Pharmacyclics; UC San Diego School of Medicine; University of California, San Diego
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Receptor tyrosine kinase-like orphan receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia
  • Phase I/II Mantle-cell lymphoma; Marginal zone B-cell lymphoma
  • No development reported Endometrial cancer; HER2 negative breast cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 28 Jul 2025 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Late-stage disease, Metastatic disease) in USA (Parenteral)
  • 27 Jun 2025 Hoola Therapeutics acquires Zilovertamab from Oncternal Therapeutics
  • 28 May 2025 No recent reports of development identified for preclinical development in Endometrial-cancer in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top